RNA control networks in COPD
Official title: Post-transcriptional regulatory networks in Chronic Obstructive Pulmonary Disease
Funded at University of Virginia · NIH-11326208 · Data updated 2026-11-12
This project looks at how proteins that control RNA affect lung cells in people with COPD.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Virginia NIH-funded |
| Lab location | 1 site (Charlottesville, United States) |
| Project start | May 1, 2025 |
| Project end | February 28, 2030 |
| Funding year | 2026 |
| Award (this year) | $673,136 |
| NIH project number | 5R01HL176576-02 |
| Project ID | NIH-11326208 on NIH RePORTER |
Who could benefit from this research
✓Could help
Adults with diagnosed COPD who can donate lung tissue, provide clinical data, or allow use of their stored biospecimens are the ideal participants.
✕Less likely to help
People without COPD, or those unable to provide tissue or clinical data, are unlikely to receive direct benefits from this project.
What this research studies
This project will map how proteins that bind RNA (called RNA-binding proteins or RBPs) control different RNA versions in lungs from people with COPD. The team will combine patient lung tissue, large RNA datasets, laboratory binding tests, and computer modeling to build networks showing which RBPs affect which RNA isoforms. They will then test key RBPs in cell experiments to see how these network changes alter protein levels and cell behavior linked to COPD. From your perspective, this work could help explain why lung cells behave differently in COPD and point to new targets or markers for future therapies.
Why it matters
Potential benefit: If successful, this work could reveal new molecular targets or biomarkers that lead to better COPD diagnostics or treatments.
How similar studies have gone: Previous transcriptomic work has identified many altered genes and some RBPs in COPD, but building detailed RBP-to-isoform regulatory networks in COPD is a newer and still-developing approach.
Where this research is happening
-
University of Virginia
Charlottesville, United States Active
Researchers
- Principal investigator: Platig, John — University of Virginia
- Study coordinator: Platig, John
Related research
Other NIH-funded projects on the same topics.
-
Ethics-aware Multimodal AI for COPD prevention, diagnosis, and treatment
A broad AI model uses diverse health data to help predict and manage COPD in people, with an emphasis on ethics and fairness.
-
Positive airway pressure therapy for older veterans with COPD and sleep apnea overlap
A plan to see if using a CPAP/BAP therapy improves sleep, thinking, and quality of life for older veterans who have both COPD and sleep apnea.
-
Understanding how microbes and our bodies shape HIV-related COPD in LMICs
This project looks at how interactions between the human body and microbes may influence COPD in people living with HIV in low- and middle-income countries.
-
Anti-EMAP II antibody as a first-in-class treatment for COPD-related pulmonary hypertension
A first-in-class antibody treatment is being developed to help people with COPD-related pulmonary hypertension by blocking EMAP II, a molecule involved in lung injury and inflammation.
-
Non-coding RNA and COPD: how RNA structure changes with disease
A COPD research project explores how non-coding RNA structures in adults with COPD change due to genetic differences and how this affects gene activity.
-
ANT2 and mitochondrial dysfunction in COPD: how energy transport affects lung repair
This project studies how a key mitochondrial transporter (ANT2) may drive aging-like cell changes and repair problems in the lungs of people with COPD.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.